CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries.
Based on the collaboration agreement, CureVac will be the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. Bayer holds further options to become Marketing Authorization Holder in other markets outside of Europe. The companies plan to combine their strengths for CureVac to be in a position to supply hundreds of millions of CVnCoV doses around the world, once approvals are granted. Together both companies aim to play a meaningful role to contribute to stopping the COVID-19 pandemic.
CureVac is currently expanding its partner network for the development, production and distribution of its vaccine candidate. In November 2020, the company announced that it would ramp up its European manufacturing network, working with Wacker and Fareva, amongst others. On December 14, 2020 the company achieved another milestone in the development of CVnCoV with the start of its global pivotal Phase 2b/3.
Further information can be found under Bayer News und unter CureVac News.